Baseline Blood-Brain Barrier Leakage and Longitudinal Microstructural Tissue Damage in the Periphery of White Matter Hyperintensities

Author(s):
Danielle Kerkhofs, MD; Sau May Wong, PhD; Eleana Zhang, PhD, MD; Julie Staals, PhD, MD; Jacobus F.A. Jansen, PhD; Robert J van Oostenbrugge, PhD, MD; Walter H Backes, PhD

Equal Author Contributions:
Danielle Kerkhofs and Sau May Wong contributed equally to the manuscript

The Article Processing Charge was funded by Maastricht University.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Abstract

Objective To investigate the two-year change in parenchymal diffusivity, a quantitative marker of microstructural tissue condition, and the relationship with baseline blood-brain barrier (BBB) permeability, in tissue at risk, i.e. the perilesional zone surrounding white matter hyperintensities (WMH) in patients with cerebral Small Vessel Disease (cSVD).

Methods Patients with sporadic cSVD (lacunar stroke or mild vascular cognitive impairment) underwent 3T MRI at baseline, including dynamic contrast-enhanced MRI to quantify BBB permeability (i.e. leakage volume and rate), and IntraVoxel Incoherent Motion imaging (IVIM), a diffusion technique that provides parenchymal diffusivity $D$. After two-years IVIM was repeated. We assessed the relation between BBB leakage measures at baseline and change in parenchymal diffusivity ($\Delta D$) over 2 years in the perilesional zones (divided in 2mm contours) surrounding WMH.

Results We analysed 43 patients (age 68±12 years, 58% male). In the perilesional zones, $\Delta D$ increased with 0.10 [CI = 0.78, 0.13]% ($p < 0.01$) per 2 mm closer to the WMH.

Furthermore, $\Delta D$ over 2 years showed a positive correlation with both baseline BBB leakage volume ($r = 0.29$ [CI = 0.06, 0.52], $p = 0.013$) and leakage rate ($r = 0.24$ [CI = 0.02, 0.47], $p = 0.034$).
Conclusion BBB leakage at baseline is related to the 2-year change in parenchymal diffusivity in the perilesional zone of WMH. These results support the hypothesis that BBB impairment might play an early role in subsequent microstructural white matter degeneration as part of the pathophysiology of cSVD.

Introduction

Cerebral small vessel disease (cSVD) is a common age and vascular risk factor related disease and may cause lacunar stroke and cognitive impairment.1 White matter hyperintensities (WMH), a radiological marker frequently found in cSVD, are assumed to be a manifestation of vascular damage to the white matter and can be considered as a surrogate marker of disease severity.2-5

Blood-brain barrier (BBB) disruption is thought to be at the basis of microstructural alterations that eventually lead to brain tissue degeneration visible as WMH on MRI. Using dynamic contrast-enhanced (DCE) MRI it was previously shown that BBB permeability is increased in cSVD and correlates to disease burden in terms of WMH load.6-10 However, WMH represent macrostructural consequences of microvascular pathology, while the tissue microstructure is likely impaired before and beyond such visible lesions. To determine the condition of the parenchymal microstructure we propose Intravoxel Incoherent Motion (IVIM) imaging, which is a diffusion-weighted MRI technique that can quantitatively measure parenchymal diffusivity without the influence or contribution of water diffusion in the blood vessels.11 It was demonstrated earlier that patients with cSVD have an increased diffusivity of the normal appearing white matter (NAWM) compared to controls.12,13

Longitudinal data on the influence of BBB permeability on microstructural alternations are needed to determine the sequence of the pathophysiological events to proclaim on a potential causal relation. In patients with cSVD, we investigated the relation between BBB
permeability at baseline and the longitudinal change in parenchymal diffusivity over two years in the perilesional zone around WMH.

**Material and Methods**

Inclusion and imaging methods of this study have been described before.\(^7,^{12,14}\)

**Study population**

In this longitudinal study, we included patients with clinically manifest cSVD, consisting of lacunar stroke or mild vascular cognitive impairment (mVCI).\(^7\) Inclusion criteria for lacunar stroke was as a first-ever acute stroke syndrome with a compatible recent small subcortical infarct on brain MRI. If no such lesion was visible on MRI, established clinical criteria for lacunar stroke syndrome were used.\(^15,16\) Exclusion criteria included a symptomatic carotid stenosis of ≥50% or a possible cardiac embolic source (e.g. atrial fibrillation). To avoid measuring acute effects, stroke patients were included at least 3 months post-stroke. Criteria for mVCI consisted of subjective cognitive dysfunction, objective cognitive impairment determined by neuropsychological assessment in at least one cognitive domain, and widespread WMH on brain MRI that suggested a link between cognitive deficit and cSVD: moderate to severe WMH (Fazekas score deep>1 and/or periventricular>2), or mild WMH (Fazekas score deep=1 and/or periventricular=2) combined with lacune(s) or microbleeds.\(^17,18\) Furthermore, patients were excluded if a neurodegenerative disease other than vascular cognitive impairment was suspected (e.g. Alzheimer's disease), or in case of severe cognitive impairment defined as a clinical Dementia Rating of > 1 or a Mini Mental State Examination score of <20. Other exclusion criteria were a history of cerebrovascular disease, or diagnoses of other central nervous system diseases or contraindications for MRI. Characteristics that were recorded at baseline included age, sex, and cardiovascular factors such as hypertension.
(history of hypertension/antihypertensive medication), hypercholesterolemia (history of hypercholesterolemia/statin), diabetes (history of diabetes/diabetes medication), current smoking and body mass index (BMI).⁷

Patients were recruited from the Maastricht University Medical Centre* and Zuyderland Medical Centre, The Netherlands, between April 2013 and February 2015. Follow-up measurements were performed after two years in the period between June 2015 and March 2017.

**Standard Protocol Approvals, Registrations, and Patient Consents**

The study was approved by the Medical Ethics Committee of the Maastricht University Medical Center*. Written informed consent was obtained from all participants (or guardians of participants) in the study (consent for research).

**Imaging**

All patients underwent brain imaging on a 3 Tesla MRI system (Achieva TX, Philips Healthcare, Best, the Netherlands) at baseline and 2-year follow-up using a 32-element head coil suitable for parallel imaging. Structural MRI included a T1-weighted sequence (repetition time (TR)/inversion time (TI)/echo time (TE)) = 8.3/800/3.8 ms; field of view (FOV) 256×256×160 mm; 1.0 mm cubic voxel size) and a T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence (TR/TI/TE = 4800/1650/299 ms; FOV 256×256×180 mm; 1.0 mm cubic voxel size) for anatomic reference and detection of WMH.⁷ ⁹

**DCE-MRI**
At baseline, dual-time resolution DCE-MRI was performed by two integrated dynamic saturation recovery gradient recalled sequences (flip angle = 10°, 90° non-selective saturation pre-pulse, time delay (TD) of 120 ms) with different dynamic scan time (DST), the fast and the slow sequence.\(^7,9,19\) First, pre-contrast scans of both the fast and slow sequences were obtained before bolus injection. Then, the contrast agent was injected (gadobutrol; dose 0.1 mmol/kg body weight) in the antecubital vein at a rate of 3 mL/s followed by a 20 mL saline flush using a power injector. During the injection, the fast sequence was applied (DST 3.2 seconds, TR/TE/TD = 5.6/2.5/120 ms, flip angle 30°, FOV 256×200×50 mm, voxel size 2×2×5 mm, image acquisition acceleration (SENSE) factor 2, 29 image volumes including 9 pre-contrast volumes, duration 1:33 min:sec). Subsequently the slow sequence (DST 30.5 seconds, TR/TE/TD = 5.6/2.5/120, flip angle 30°, FOV 256×256×100 mm, voxel size of 1×1×2 mm, SENSE factor 2, 45 image volumes including 3 pre-contrast volumes, duration 22:53 min:sec) was performed. The fast and slow sequences overlapped spatially with the periventricular region, the most vulnerable region in cSVD patients.\(^20\) T1-mapping with variable delay time (TD, 120 – 4000 ms) was performed before contrast agent administration and DCE-MRI to convert the contrast enhanced signal intensities to concentrations in tissue.\(^21\)

**IVIM imaging**

At baseline and 2-year follow-up, IVIM imaging was conducted as described before.\(^12,22\) We employed a Stejskal-Tanner diffusion-weighted (DW) single shot spin-echo echo-planar-imaging pulse sequence (TR/TE = 6800/84ms; FOV 221× 269×139 mm\(^3\); 2.4 mm\(^3\) cubic voxel size; duration 5:13 min:sec). To minimize the signal contribution of CSF, an inversion recovery pulse (TI = 2230 ms) was applied prior to the DW sequence.\(^23\) Fifteen volume images were acquired with the diffusion sensitization gradient encoding in the anterior-posterior direction using multiple \(b\)-values (0, 5, 7, 10, 15, 20, 30, 40, 50, 60, 100, 200, 400,
700, and 1000 s/mm². To increase the signal-to-noise ratio at high b-values the number of signal means for the highest two b-values were two and three, instead of one, respectively.¹²

**Image processing and analyses**

**DCE-MRI**

*Pharmacokinetic modelling*

Analysis of the DCE-MRI data consists of pharmacokinetic modeling and histogram analysis as described before.⁷,¹⁹ For this purpose the graphical Patlak method was employed to relate concentration time-course of brain tissue and blood.²⁴ For this method the contrast agent concentration in tissue was calculated by using the relative signal enhancement, T1-mapping and the concentration in blood plasma in the superior sagittal sinus as the vascular input function.²¹ Using the slope in the Patlak plot, the transfer constant $K_i$ (min⁻¹) was calculated as a measure of leakage rate.

*Histogram analysis*

$K_i$ was determined in a voxel-wise manner and a histogram was composed of the $K_i$-values in each tissue region, as described earlier.¹⁴ Noise correction was achieved by mirroring the negative $K_i$ values to the positive axis and subtracting both parts from the original $K_i$ distribution, resulting in a histogram of (the remaining positive) $K_i$-values which reflect the detectable leakage rates. Quantitative measures of BBB leakage per tissue region were obtained from this histogram: the mean $K_i$, was calculated as the mean of all the positive noise-corrected voxels, and the leakage volume ($v_L$), which was the total residual area under the (positive) histogram curve, representing the spatial extent of the leakage.⁷

**IVIM imaging**
Preprocessing of the IVIM images has been described previously and consisted of spatial distortion corrections (EPI and eddy current distortions) and head displacements (ExploreDTI v.4.8.3 and v.4.8.6).\textsuperscript{12,22,25} Subsequently, baseline and follow-up IVIM images were co-registered to the corresponding baseline T1-weighted image and spatially smoothed with a 3 mm full-width-at-half-maximum Gaussian kernel. The IVIM signal decay was fitted with a bi-exponential curve by using a modified two-compartment diffusion model representing a vascular and a non-vascular component, which also accounts for contamination of CSF and differences in relaxation time between tissue and blood.\textsuperscript{23} The vascular component is thought to embody the fast water motion in blood flowing into a random network of small vessels and the non-vascular component is determined by the water diffusion in the parenchymal microstructure represented by the parenchymal diffusivity $D$. Model fitting was performed on a voxel-by-voxel basis using a two-step method separating the mono-exponential decay at the high b-values from the bi-exponential decay at the lowest b-value.\textsuperscript{26} This resulted in the parenchymal diffusivity $D$, which was corrected for fast water motion in blood and was calculated for the baseline and follow-up scans. The relative change in $D$ over time was calculated as follow: $\Delta D(\%) = 100 \times \frac{(D_{\text{Follow-up}} - D_{\text{Baseline}})}{D_{\text{Baseline}}}$.

**Tissue regions**

Grey and white matter were segmented (Freesurfer\textsuperscript{27}) in the baseline T1-weighted images. WMH were automatically segmented, with manual correction by a trained investigator under supervision of two experienced vascular neurologists, on baseline FLAIR-scans.\textsuperscript{28} All images were co-registered to the DCE-MRI space: baseline FLAIR and T1-weighted images, baseline and follow-up IVIM images were co-registered to the pre-contrast DCE-MRI scans (FSL, v5.0).\textsuperscript{29} The following brain regions were selected: CGM, NAWM, WMH and. The volume of WMH was normalized to the intracranial volume to calculate relative WMH volume.
Next, the perilesional zone adjacent to WMH was selected: the NAWM was divided into a number of perilesional shells by segmenting 6 contours of 2-mm width using a dilation operation of 2 mm around the WMH.\textsuperscript{14} For all tissue regions and the perilesional zones baseline BBB-measures, $K_i$ and $v_L$, and IVIM measures, $D_{\text{Baseline}}$, $D_{\text{Follow-up}}$ and $\Delta D(\%)$, were calculated.

**Statistical analysis**

Leakage and diffusivity measures were compared between the different tissue regions (Cortex, NAWM and WMH) using a paired $t$-test. For each tissue region, univariable regression analysis was performed between the baseline BBB measures ($K_i$ and $v_L$) as independent variable and the longitudinal change in parenchymal diffusivity ($\Delta D$) as dependent variable.

For the perilesional zone, regression analysis was performed between mean baseline BBB measures and distance to WMH, and between mean $\Delta D$ and distance to WMH. Then, two analyses were performed to investigate the relation between the baseline BBB measures and $\Delta D$ within the perilesional zone: 1) Per patient, the spatial relation between the leakage measures and longitudinal change in parenchymal diffusivity $\Delta D$ was assessed as a function of distance to the WMH using the Pearson correlation. 2) Per contour of the perilesional zone, the mean leakage measures and mean longitudinal diffusivity change $\Delta D$ over all patients were calculated. The spatial relation between the mean leakage measures and mean longitudinal diffusivity change $\Delta D$ was studied using linear regression. All statistical analyses were performed using SPSS version; $p<0.05$ was considered as statistically significant.

**Data availability**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results

Patient characteristics

At baseline 81 patients with cSVD were included. We obtained follow-up data for 51 of these patients, 4 patients died during follow-up period and 26 patients were not willing to participate in the follow-up study. Eight additional patients were excluded from data analysis due to imaging complication or artifacts at baseline and/or follow-up. The 43 patients suitable for analysis did not differ from the patients who only completed baseline measurements regarding sex (male 58.1% vs 57.9% respectively, \( p = 0.983 \)), but were younger (67.7 ± 12.0 years vs 72.6 ± 9.8 years, respectively, \( p = 0.048 \)). The relative WMH volume at baseline was not different for the patients included in this study as compared to the patients with only baseline data (0.013 ± 0.013 vs 0.017 ± 0.016, respectively, \( p = 0.266 \)). The mean time between baseline and follow-up MRI scan was 25 ± 1 months. The characteristics of included patients are shown in Table 1.

Cortex, white matter and white matter hyperintensities

First, we analyzed the cortical grey matter, normal appearing white matter, and white matter hyperintensities. The mean baseline values of leakage volume \( v_L \) and leakage rate \( K_i \) for these brain regions are presented in Table 2. Both leakage volume \( v_L \) and leakage rate \( K_i \) were higher in the WMH than in the NAWM (mean difference [95% confidence interval (CI)] \( v_L: 6.1 [1.3, 9.6]\% , p = 0.001; K_i: 0.30 [0.04, 0.55] \times 10^{-4} \text{ min}^{-1} , p = 0.023 \)) and higher in the NAWM than in the CGM (\( v_L: 15.7 [12.6, 18.8]\% , p <0.001; K_i: 0.98 [0.63, 1.33] \times 10^{-4} \text{ min}^{-1}, p <0.001 \)).
The mean values of baseline diffusivity \( D_{\text{Baseline}} \), follow-up diffusivity \( D_{\text{Follow-up}} \) and the longitudinal change in diffusivity \( \Delta D \) for all tissue regions are also presented in Table 2. Both baseline diffusivity \( D_{\text{Baseline}} \) and follow-up diffusivity \( D_{\text{Follow-up}} \) were higher in the WMH than in the NAWM (mean difference \( D_{\text{Baseline}} \): 1.47 [1.27, 1.67] \times 10^{-4} \, \text{mm}^2/\text{s}, p <0.001; \) \( D_{\text{Follow-up}} \): 1.51 [1.28, 1.75] \times 10^{-4} \, \text{mm}^2/\text{s}, p <0.001) and higher in the NAWM than in the CGM (\( D_{\text{Baseline}} \): 0.07 [0.01, 0.12] \times 10^{-4} \, \text{mm}^2/\text{s}, p =0.024; \) \( D_{\text{Follow-up}} \): 0.08 [0.02, 0.14] \times 10^{-4} \, \text{mm}^2/\text{s}, p =0.009). The longitudinal change in diffusivity \( \Delta D \) was highest in WMH and lowest in CGM but these were not significant different. There was no association between the baseline leakage measures \( v_L \) and \( K_i \) and change in diffusivity \( \Delta D \) over 2 years in any of these tissue regions (Table 3).

**Perilesional zones**

In Fig. 1, example maps of the perilesional zones, leakage rate \( K_i \) and parenchymal diffusivity \( D \) are shown. In Fig. 2 we present the mean values of leakage volume \( v_L \), leakage rate \( K_i \), and longitudinal change in diffusivity \( \Delta D \) over the 2mm contours of the perilesional zones. Regression analysis of BBB leakage near the WMH showed that both BBB leakage volume and leakage rate increase in proximity to the lesion: leakage volume increases with 0.7 [0.4, 1.0]% (\( p < 0.01 \)) and leakage rate with 0.30 [0.09, 0.51] \times 10^{-5} \, \text{min}^{-1} (p = 0.018) per 2 mm closer to the WMH. Also, the longitudinal change in diffusivity \( \Delta D \) was higher adjacent to the WMH compared with zones that are more distant: \( \Delta D \) of 2.0% compared to 1.0% in respectively 2 and 12 mm distance from WMH borders. \( \Delta D \) increases with 0.10 [0.78, 0.13]% (\( p < 0.01 \)) per 2 mm closer to the WMH.

Two analyses were performed to investigate the relation between the leakage measures and the longitudinal change \( \Delta D \) in the perilesional zone. First, for every individual patient, we investigated the longitudinal change in diffusivity \( \Delta D \) over the zones surrounding the WMH.
in correlation to baseline leakage volume $v_L$ and leakage rate $K_i$. Both baseline leakage volume $v_L$ and leakage rate $K_i$ showed a significant positive correlation with the longitudinal change in diffusivity $\Delta D$ over the zones around the WMH ($v_L : r = 0.29 \ [0.06, 0.52], p = 0.013; K_i : r = 0.24 \ [0.02, 0.47], p = 0.034)$. We further tested if the individual correlations between baseline leakage and change in diffusivity are associated with different risk factors (including age, sex, hypertension, Diabetes type II, Fazekas score, and relative WMH volume). No associations were found between the risk factors and the individual correlations (data not shown, available upon request).

In the second analysis, the relation between the mean leakage volume $v_L$ and mean leakage rate $K_i$, and the mean longitudinal change in diffusivity $\Delta D$ over all patients in the WMH perilesional zones is presented in Fig. 3. Both leakage volume and leakage rate are significantly associated with the longitudinal change in diffusivity $\Delta D$ around the WMH: per 10% higher baseline leakage volume $v_L$, the longitudinal change in diffusivity $\Delta D$ increases 1.4% ($\beta = 0.960, p = 0.002$) and per $1 \times 10^{-3}$ min$^{-1}$ higher leakage rate $K_i$, the longitudinal change in diffusivity $\Delta D$ increases 2.7% ($\beta = 0.895, p = 0.016$).

**Discussion**

In this longitudinal study in patients with cSVD, we examined BBB leakage at baseline in relation to change in parenchymal diffusivity over two years in the perilesional zones of WMH. We found that the longitudinal increase in parenchymal diffusivity over 2 years, representing decrease in microstructural tissue integrity, was higher adjacent to the WMH in comparison to more remotely located NAWM. This stronger longitudinal increase in parenchymal diffusivity in the proximity of the WMH was positively associated with locally higher BBB leakage volume and rate at baseline.
Loss of tissue integrity in the NAWM directly surrounding the WMH is of increasing interest as it has been shown to precede conversion into WMH over time.\textsuperscript{30, 31} Furthermore, it has been demonstrated that loss of tissue integrity of the NAWM was associated with cognitive performance in cSVD patients.\textsuperscript{32} Loss of tissue integrity is represented by increased brain tissue water measured with IVIM as an increased parenchymal diffusivity.\textsuperscript{33} In agreement with cross-sectional studies, we showed increased diffusivity closer towards WMH, and in addition we found the change in diffusivity over time increasing in proximity to WMH.\textsuperscript{10, 34} The longitudinal change in diffusivity in the closest perilesional contours was even higher than in the WMH itself, reflecting that the perilesional zones are really at risk. Probably, tissue within WMH is damaged already to such an extent that further tissue loss is attenuating.

Increase in permeability of the BBB is assumed to play an initiating and important role in the pathogenesis of cSVD. Leakage of the BBB is associated with total WMH volume and predicts cognitive decline.\textsuperscript{9, 10} Similar to our study, BBB permeability in the white matter was previously found to be increased in the proximity to WMH.\textsuperscript{10, 14, 35}

In the present study, which has a longitudinal set-up, we show that BBB leakage measured at baseline in the perilesional zones surrounding the WMH is spatially related to a higher increase in tissue diffusivity over 2 years. This observed link between BBB leakage at baseline and loss of microstructural integrity over time in the zones around the WMH, is a novel finding that supports the idea that increased permeability of the BBB leads to microstructural damage before (extension of) morphological abnormalities become visible on brain MRI as WMH.\textsuperscript{36, 37} The neurovascular unit (NVU) is an important component in the brain regulating the functioning of the BBB as a selective barrier and thereby maintaining a healthy tissue environment. Impairment of the BBB can influence other elements of the NVU including changes in extracellular matrix components, pericytes and inflammatory cells, which affect the local brain tissue.\textsuperscript{38-40} Our results are in line with the hypothesis that there is
an impaired functioning of the NVU in cSVD as also shown in a previous study, where BBB impairment was related to hypoperfusion.\textsuperscript{14}

In contrast to the perilesional zones around the WMH, we did not observe an association between longitudinal change in diffusivity and BBB leakage in the larger tissue regions (i.e. total NAWM, CGM or WMH). The CGM and NAWM tissue regions are probably too large and heterogeneous and disguise local pathophysiological effects such as in the perilesional zone. Furthermore, as WMH already comprises tissue with abnormal tissue integrity and decreased perfusion, this could explain why we do not find an association between BBB leakage and change in tissue integrity in the WMH.\textsuperscript{41}

Short-term progression of cSVD is difficult to monitor as visible MRI markers such as WMH progress slowly over time. Parenchymal diffusivity has been shown to be the most promising measure to detect longitudinal changes.\textsuperscript{42} We demonstrated in the present study the possibility to detect microstructural changes over two years in the vulnerable tissue surrounding the visible WMH with IVIM imaging. Parenchymal diffusivity in the proximity of WMH can be a promising quantitative biomarker for monitoring on prevention and treatment efficacy in trials in cSVD.

A major strength of the current study is the longitudinal design. It enabled us to investigate a temporal relation between BBB leakage and longitudinal change in microstructural integrity. Identical IVIM sequences on the same MR scanner were used during baseline and follow-up which makes direct comparison of both scans straightforward. Furthermore, IVIM provides a less contaminated measure for parenchymal diffusivity compared to standard diffusion MRI. The correction for the vascular contribution with IVIM imaging is important to avoid direct influence from microvascular perfusion, which is also altered in the perilesional zones.\textsuperscript{14} BBB permeability was assessed for both leakage volume and leakage rate. Leakage volume is a relative new measure to examine BBB permeability. We previously found that leakage
volume is higher in cSVD patients compared to age- and sex- matched controls, indicating that leakage volume is a sensitive measure for BBB leakage.\textsuperscript{7}

A limitation of this study is that the short follow-up period may have underestimated the associations found in this study. However, the relatively short period underlines the susceptibility of the IVIM technique and emphasizes the early role of the BBB breakdown (and NVU impairment) for the limited time for other pathophysiological processes to interfere. Future studies should examine longitudinal change in microstructural integrity in a larger patient cohort over a longer time period, and also in subjects with less WMH load. Another limitation of this study is that we only assessed BBB permeability at baseline. Therefore we have no indication of any change in BBB permeability over time and the association with tissue degeneration, which would be of interest for future studies. Furthermore, it is conceivable that the association between BBB leakage and longitudinal increasing diffusivity is due to another common underlying factor or mechanism.

In conclusion, in patients with cSVD we showed that the increase in parenchymal diffusivity over two years was strongest in proximity of the WMH (and even higher than within WMH itself). Our results also demonstrate that BBB leakage at baseline is related to this change in perilesional white matter diffusivity, and therefore tissue integrity. This observation supports the hypothesis that BBB impairment plays an early and pivotal role in subsequent microstructural white matter degeneration and the pathophysiology of cSVD. In the future, measures of BBB leakage may be used to identify patients at risk for development and progression of tissue degeneration. The longitudinal change in parenchymal diffusivity measured with IVIM is a promising quantitative biomarker for monitoring in cSVD trials.

Acknowledgements
The authors thank Dr Erik Hoff and Tobien Schreuder for help with recruitment.

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 666881, SVDs@target; NWO (Netherlands Organisation for Scientific Research), grant: 017.009.048; Hersenstichting, grant: 2013(1)-195; and Stichting de Weijerhorst foundation.

Disclosures

The authors report no disclosures relevant to the manuscript.

Appendix 1. Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Kerkhofs, MD</td>
<td>Maastricht University,</td>
<td>Drafting/revising the manuscript,</td>
</tr>
<tr>
<td></td>
<td>The Netherlands</td>
<td>analysis or interpretation of the data, statistical analysis</td>
</tr>
<tr>
<td>Sau May Wong, PhD</td>
<td>Maastricht University,</td>
<td>Drafting/revising the manuscript, data acquisition, analysis or interpretation of the data</td>
</tr>
<tr>
<td></td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Eleana Zhang, MD, PhD</td>
<td>Maastricht University,</td>
<td>Data acquisition, review of manuscript</td>
</tr>
<tr>
<td></td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Julie Staals, MD, PhD</td>
<td>Maastricht University,</td>
<td>Drafting/revising the manuscript, study concept or design, analysis or interpretation of the data</td>
</tr>
<tr>
<td></td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Jacobus F.A. Jansen, PhD</td>
<td>Maastricht University,</td>
<td>Drafting/revising the manuscript, data acquisition, study concept or design, analysis or interpretation of the data</td>
</tr>
<tr>
<td></td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Robert J. van Oostenbrugge,</td>
<td>Maastricht University,</td>
<td>Drafting/revising the manuscript,</td>
</tr>
<tr>
<td>MD</td>
<td>The Netherlands</td>
<td>study concept or design, analysis or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>interpretation of the data</td>
</tr>
</tbody>
</table>
References

### Tables

**Table 1: Characteristics of the study population**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=43</td>
<td></td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>68 (12)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>25 (58)</td>
</tr>
<tr>
<td>Lacunar stroke /mVCI (%)</td>
<td>30 (70)/ 13 (30)</td>
</tr>
<tr>
<td>Time to Follow-up MRI, months (SD)</td>
<td>25 (1)</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>27 (63)</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>13 (30)</td>
</tr>
<tr>
<td>Hypercholesterolemia (%)</td>
<td>27 (63)</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>BMI, kg/m² (SD)</td>
<td>25 (4)</td>
</tr>
<tr>
<td>Total WMH Fazekas score, median (IQR)</td>
<td>4 (2-6)</td>
</tr>
<tr>
<td>Relative WMH volume (SE)</td>
<td>0.013 (0.002)</td>
</tr>
</tbody>
</table>

SD, Standard deviation; IQR, Interquartile range; SE, Standard error; mVCI, mild vascular cognitive impairment; BMI, Body Mass Index. Total Fazekas score: Periventricular (0-3) and deep (0-3) WMH scores were summed.

Table 2: Leakage volume $v_L$ and leakage rate $K_i$ for the different brain regions. Notation: mean ± SEM

<table>
<thead>
<tr>
<th>MRI measure</th>
<th>Brain region</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NAWM</td>
</tr>
<tr>
<td>$v_L$ (%)</td>
<td>31.1 ± 2.3</td>
</tr>
<tr>
<td>$K_i$ ($\times 10^{-4}$ min$^{-1}$)</td>
<td>3.05 ± 0.25</td>
</tr>
<tr>
<td>$D_{\text{Baseline}}$ ($\times 10^{-4}$ mm$^2$/s)</td>
<td>7.37 ± 0.05</td>
</tr>
<tr>
<td>$D_{\text{Follow-up}}$ ($\times 10^{-4}$ mm$^2$/s)</td>
<td>7.46 ± 0.06</td>
</tr>
<tr>
<td>$\Delta D$ (%)</td>
<td>1.20 ± 0.30</td>
</tr>
</tbody>
</table>

NAWM, Normal appearing white matter; WMH, White matter hyperintensities; CGM: Cortical grey matter; $v_L$, leakage volume; $K_i$, leakage rate; $D_{\text{Baseline}}$, baseline diffusivity; $D_{\text{Follow-up}}$, follow up diffusivity; $\Delta D$, relative change in diffusivity.
Table 3: Association between longitudinal change in diffusivity $\Delta D$ and leakage volume $v_L$ and leakage rate $K_i$

<table>
<thead>
<tr>
<th></th>
<th>$v_L$</th>
<th>$K_i$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\Delta D$</td>
<td>$\beta$</td>
<td>$p$-value</td>
</tr>
<tr>
<td>NAWM</td>
<td>-0.071</td>
<td>0.650</td>
</tr>
<tr>
<td>WMH</td>
<td>0.237</td>
<td>0.130</td>
</tr>
<tr>
<td>CGM</td>
<td>-0.025</td>
<td>0.874</td>
</tr>
</tbody>
</table>

NAWM, Normal appearing white matter; WMH, White matter hyperintensities; CGM: Cortical grey matter; $v_L$, leakage volume; $K_i$, leakage rate; $\Delta D$, relative change in diffusivity
Figure legends

Figure 1. FLAIR image, perilesional zones, and leakage and diffusivity maps.

FLAIR-image at baseline (A), perilesional zones at baseline (B), leakage rate ($K_i$) map at baseline (C) and the parenchymal diffusion maps at baseline (D) and follow-up (E) from a patient with cSVD (Female, 52 years).
Figure 2. Leakage volume, leakage rate and longitudinal change in parenchymal diffusivity for the perilesional zones.

Spatial variation in leakage volume $v_L$ (A), leakage rate $K_i$ (B) and longitudinal change in parenchymal diffusivity $\Delta D$ (C) in the perilesional zones around the WMH. Corresponding regression lines of the values per perilesional zone are plotted (dashed).
Figure 3. Scatterplots between longitudinal change in parenchymal diffusivity, leakage volume, and leakage rate.

Scatterplot between leakage volume $v_L$ (%) and longitudinal change in parenchymal diffusivity $\Delta D$ (%) (A), and between leakage rate $K_i \times 10^{-4}$ min$^{-1}$ and longitudinal change in parenchymal diffusivity $\Delta D$ (%) (B) in the perilesional zones around the WMH with corresponding regression line.
Baseline Blood-Brain Barrier Leakage and Longitudinal Microstructural Tissue Damage in the Periphery of White Matter Hyperintensities
Danielle Kerkhofs, Sau May Wong, Eleana Zhang, et al.

Neurology published online March 24, 2021
DOI 10.1212/WNL.0000000000011783

This information is current as of March 24, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2021/03/01/WNL.0000000000011783.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
MRI
http://n.neurology.org/cgi/collection/mri
Other cerebrovascular disease/Stroke
http://n.neurology.org/cgi/collection/other_cerebrovascular_disease__stroke

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise